Navigation Links
OncoGenex Reports Third Quarter Financial Results
Date:11/10/2008

strengthening our product pipeline while streamlining our business to efficiently maximize our cash resources," said Scott Cormack, President and Chief Executive Officer of OncoGenex. "We have three programs - OGX-011, OGX-427, and SN2310 - now with robust data packages in various stages of clinical development representing attractive investment opportunities for new and existing shareholders as well as potential partners."

Recent Business Highlights:

- On August 21, 2008, Sonus Pharmaceuticals, Inc. and OncoGenex

Technologies Inc. completed a transaction, whereby Sonus acquired all

of the outstanding securities and convertible debentures of OncoGenex

Technologies. Sonus changed its name to OncoGenex Pharmaceuticals,

Inc. and was listed on the Nasdaq Capital Market under the ticker

symbol OGXI. Concurrent with the completion of the transaction there

was a workforce reduction of 49% of the employees of the two

companies in order to effectively utilize cash assets while

maintaining the resources to advance our priority clinical programs.

The Company has 24 full-time employees after giving effect to the

above workforce reduction.

- OncoGenex and Isis amended the development agreement for OGX-011,

providing OncoGenex with increased economic interest in OGX-011 and

increased flexibility to further develop this product candidate. In

addition, we believe this new arrangement facilitates future

partnering discussions since potential development and

commercialization partners need only deal with one party.

- OncoGenex reached an agreement with the FDA on the design of a Phase

3 registration trial of OGX-011, its lead product candidate targeting

hormone refractory prostate cancer, via the SPA process. In the

letter responding to the OncoGenex submission, the
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
8. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
9. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 20, 2014 Mapp Biopharmaceutical,s valiant effort ... therapeutic to fight the Ebola outbreak will make ... the production of pharmaceuticals can be, according to ... that while some may be taken aback by ... with industry knowledge are well aware of the ...
(Date:10/20/2014)... 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") ... orders to $5.8 million and provides a good start to Q4.  ... North America and one in the Middle ... at record levels," said Peter Bruijns , President & CEO. ... of Q3 than they have been for any complete year since ...
(Date:10/20/2014)... Oct. 20, 2014 PureTech , a ... big healthcare problems, announced today the closing of ... participation from Invesco Perpetual, a $120 Billion group ... drive PureTech,s existing pipeline forward and to advance ... the scientific creativity to really go for the ...
(Date:10/20/2014)... Local veterinary surgeon, Dr. Tim McCarthy is ... donor stem cells for dogs with osteoarthritis. Dr. McCarthy ... performed clinical stem cell therapy for 7 years. The ... a single injection of donor stem cells into one ... and inflammation in the treated joints. , Candidates ...
Breaking Biology Technology:Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6Cascade Veterinary Referral Center Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2
... Sigma Life Science, the innovative biological ... SIAL ), announced that its SAGE Labs initiative ... Parkinson,s disease in collaboration with The Michael J. Fox ... SAGEspeed™ model creation process, these off-the-shelf rat models represent ...
... size, antennaswhether in a cell phone or on ... and bandwidth when their size is reduced below ... toward producing antennas by screen-printing, inkjet printing, and ... dipoles and loops," explained Jennifer T. Bernhard, a ...
... 16, 2011 Reportlinker.com announces that a new ... Global Growth Factors ( ... http://www.reportlinker.com/p0397766/Global-Growth-Factors--Blood-And-Tissue--Industry.html This report ... And Tissue) in US$ Million by the following ...
Cached Biology Technology:Sigma® Life Science Launches Suite of Knockout Rats to Model Parkinson's Disease 2Sigma® Life Science Launches Suite of Knockout Rats to Model Parkinson's Disease 33-D printing method advances electrically small antenna design 2Global Growth Factors ( Blood And Tissue ) Industry 2Global Growth Factors ( Blood And Tissue ) Industry 3Global Growth Factors ( Blood And Tissue ) Industry 4Global Growth Factors ( Blood And Tissue ) Industry 5Global Growth Factors ( Blood And Tissue ) Industry 6Global Growth Factors ( Blood And Tissue ) Industry 7Global Growth Factors ( Blood And Tissue ) Industry 8Global Growth Factors ( Blood And Tissue ) Industry 9Global Growth Factors ( Blood And Tissue ) Industry 10Global Growth Factors ( Blood And Tissue ) Industry 11Global Growth Factors ( Blood And Tissue ) Industry 12Global Growth Factors ( Blood And Tissue ) Industry 13Global Growth Factors ( Blood And Tissue ) Industry 14Global Growth Factors ( Blood And Tissue ) Industry 15Global Growth Factors ( Blood And Tissue ) Industry 16
(Date:10/14/2014)... – High doses of fish oil supplements, rich in omega-3 ... of irregular heartbeat in which the heart can beat as ... AFFORD trial led by the Montreal Heart Institute were published ... on October 7th. , For the trial, 337 patients ... assigned to 4 grams of fish oil a day or ...
(Date:10/14/2014)... This week, an international team of researchers, led by ... in the journal Nature Genetics a brief ... 360 varieties of the tomato plant. , The C.M. ... an important role in this study by providing seed ... , This study, which builds on the first tomato ...
(Date:10/14/2014)... – Researchers from Stanford University School of Medicine have ... cells and the activation of muscle stem cells. Cells ... energy during times of nutrient deprivation. The scientists report ... protective mechanism is operational it also seems to assist ... that when stem cells emerge from a quiescent state ...
Breaking Biology News(10 mins):Autophagy helps fast track stem cell activation 2
... comforting thought unless the living thing in question is a ... developing drug resistance, outwitting immune systems, and evading cellular controls. ... perturbations such as mutations that affect the function of vital ... perform old tasks. Somehow the bad guys find ...
... The delicate lady bug in your garden could be frighteningly ... in the air, a new study concludes. The study adds ... during the late Paleozoic period because they had a much ... , The study, "No giants today: tracheal oxygen supply to ...
... new approach to treating severe nerve pain ?by aiming drugs ... University of Utah scientists who study the venoms of deadly, ... way to treat a chronic and debilitating form of pain ... J. Michael McIntosh, a University of Utah research professor of ...
Cached Biology News:Evolution and the workaround 2Giant insects might reign if only there was more oxygen in the air 2Giant insects might reign if only there was more oxygen in the air 3A new target for painkillers 2A new target for painkillers 3A new target for painkillers 4
... These 1.5L PYREX trypsinizing ... homogenous tissue samples into cell ... proteins. Heavy beaded neck accepts ... enhance vigorous agitation. • Height ...
... of purified RNA samples., , This product ... aqueous RNA samples that have been pre-purified ... silica, oligo dT etc or other kits. ... necessary components for the stabilization of nanogram ...
Plasmid expressing the LacZ reporter gene....
Puromycin resistance gene (pac), provided in a pORF plasmid. pORF is an expression plasmid selectable with Ampicillin....
Biology Products: